What is the meaning of LIFE? Implications of the Losartan Intervention for Endpoint reduction in hypertension trial for heart failure physicians

被引：3
作者：
Massie, BM [1 ]
机构：
[1] Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA
来源：
JOURNAL OF CARDIAC FAILURE | 2002年 / 8卷 / 04期
关键词：
D O I：
10.1054/jcaf.2002.127612
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：197 / 201
页数：5
相关论文
共 18 条
  • [1] [Anonymous], 2000, Lancet, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7
  • [2] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [3] A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
    Cohn, JN
    Tognoni, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) : 1667 - 1675
  • [4] Dahlof B, 1997, AM J HYPERTENS, V10, P705
  • [5] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311) : 995 - 1003
  • [6] Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial
    Hansson, L
    Lindholm, LH
    Niskanen, L
    Lanke, J
    Hedner, T
    Niklason, A
    Luomanmäki, K
    Dahlöf, B
    de Faire, U
    Mörlin, C
    Karlberg, BE
    Wester, PO
    Björck, JE
    [J]. LANCET, 1999, 353 (9153) : 611 - 616
  • [7] Randomised trial of old and new antihypertensive drugs in elderly patients:: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
    Hansson, L
    Lindholm, LH
    Ekbom, T
    Dahlöf, B
    Lanke, J
    Scherstén, B
    Wester, PO
    Hedner, T
    de Faire, U
    [J]. LANCET, 1999, 354 (9192) : 1751 - 1756
  • [8] THE EPIDEMIOLOGY OF HEART-FAILURE - THE FRAMINGHAM-STUDY
    HO, KKL
    PINSKY, JL
    KANNEL, WB
    LEVY, D
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 22 (04) : A6 - A13
  • [9] The progression from hypertension to congestive heart failure
    Levy, D
    Larson, MG
    Vasan, RS
    Kannel, WB
    Ho, KKL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (20): : 1557 - 1562
  • [10] Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    Lewis, EJ
    Hunsicker, LG
    Clarke, WR
    Berl, T
    Pohl, MA
    Lewis, JB
    Ritz, E
    Atkins, RC
    Rohde, R
    Raz, I
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 851 - 860
12